

Clinical trials of VKA

TrialResults-center www.trialresultscenter.org

1 venous thrombosis

| Trial | Treatments | Patients | Trials design and methods |
|--|---|--|---------------------------|
| VKA vs control | | | |
| AUREC FVII , 2009 n=17/17 follow-up: 37 months mean | continue VKA for additional 24 months versus discontinuation | patients with first spontaneous VTE and FVIII levels >230 IU/dl after 6 monthsh of VKA | |
| DACUS (Siragusa) , 2008 [NCT00438230] n=88/92 follow-up: | anticoagulants for 9 additional months versus no treatment | with a first episode of deep vein thrombosis, treated with OAT for 3 months and with Residual vein thrombosis | |
| DURAC II , 1997 n=116/111 follow-up: 4 years | anticoagulant therapy continued indefinitely versus six months of oral anticoagulant therapy | patients who had had a second episode of venous thromboembolism | |
| PROLONG (Palarati) , 2006 [NCT00264277] n=105/122 follow-up: 1.4 years | resume treatment versus discontinue treatment | patients with a first unprovoked proximal deep-vein thrombosis or pulmonary embolism who had received a vitamin K antagonist for at least 3 months and with abnormal D-dimer testing 1 month after the discontinuation of anticoagulation | |
| WODIT DVT , 2001 n=134/133 follow-up: at least two years | continuation for nine additional months versus discontinuation | Patients with a first episode of idiopathic proximal deep venous thrombosis who had completed three months of oral anticoagulant therapy | |
| WODIT PE , 2003 n=165/161 follow-up: | - | patients after a first episode of pulmonary embolismwho had had 3 months of oral anticoagulant therapy without experiencing recurrence or bleeding | |
| DDOAT2006 ongoing [NCT00895505] n=300 follow-up: 24 months | Extension of OAT versus discontinuation | - | |
| VKA vs placebo | | | |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|---|--|--|---------------------------|
| PADIS-PE (Couturaud) , 2015 [NCT00740883] n=184/187 follow-up: | additional 18-month treatment with warfarin versus placebo | patients who had experienced a first episode of symptomatic unprovoked pulmonary embolism (ie, with no major risk factor for thrombosis) and had been treated initially for 6 uninterrupted months with a vitamin K antagonist | double-blind |

More details and results :

- antithrombotics for venous thrombosis in secondary prevention - 2 at <http://www.trialresultscenter.org/go-Q682>

References

AUREC FVII, 2009:

Eischer L, Gartner V, Schulman S, Kyrle PA, Eichinger S 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII. *Ann Hematol* 2009;88:485-90 [18931845] [10.1007/s00277-008-0626-1](https://doi.org/10.1007/s00277-008-0626-1)

DACUS (Siragusa), 2008:

Siragusa S, Malato A, Anastasio R, Cigna V, Milio G, Amato C, Bellisi M, Attanzio MT, Cormaci O, Pellegrino M, Dolce A, Casuccio A, Bajardi G, Mariani G Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. *Blood* 2008;112:511-5 [18497320] [10.1182/blood-2008-01-131656](https://doi.org/10.1182/blood-2008-01-131656)

DURAC II, 1997:

Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lrfars G, Leijd B, Linder O, Loogna E The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. *N Engl J Med* 1997;336:393-8 [9010144] [10.1056/NEJM199702063360601](https://doi.org/10.1056/NEJM199702063360601)

PROLONG (Palarati), 2006:

Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AW, Tripodi A D-dimer testing to determine the duration of anticoagulation therapy. *N Engl J Med* 2006;355:1780-9 [17065639]

WODIT DVT, 2001:

Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. *N Engl J Med* 2001;345:165-9 [11463010] [10.1056/NEJM200107193450302](https://doi.org/10.1056/NEJM200107193450302)

WODIT PE, 2003:

Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, Imberti D, Poggio R, Ageno W, Pogliani E, Porro F, Zonzin P Extended oral anticoagulant therapy after a first episode of pulmonary embolism. *Ann Intern Med* 2003;139:19-25 [12834314]

DDOAT2006, :

ongoing trial NCT00895505

PADIS-PE (Couturaud), 2015:

Couturaud F, Sanchez O, Pernod G, Mismetti P, Jago P, Duhamel E, Provost K, dit Sollier CB, Presles E, Castellant P, Parent F, Salaun PY, Bressollette L, Nonent M, Lorillon P, Girard P, Lacut K, Gagan M, Bosson JL, Laporte S, Leroyer C, Dcousus H, Meyer Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial. JAMA 2015;314:31-40 [26151264] [10.1001/jama.2015.7046](https://doi.org/10.1001/jama.2015.7046)